AnGes. has filed a patent for RNA molecules with specific sequences to modify mutant alleles of the LRRK2 gene associated with Parkinson’s disease. The method involves introducing a composition containing CRISPR nuclease and a specific RNA molecule to induce a double-strand break in the mutant allele. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AnGes Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Crispr-based method for modifying mutant lrrk2 gene in cells

Source: United States Patent and Trademark Office (USPTO). Credit: AnGes Inc

A patent application (Publication Number: US20240000970A1) describes a method for modifying a mutant allele of the Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) gene associated with monogenic Parkinson's disease. The method involves introducing a composition containing a CRISPR nuclease and a first RNA molecule with a guide sequence portion targeting the mutation in the LRRK2 gene. This complex induces a double-strand break in the mutant allele, allowing for precise genetic modifications.

Furthermore, the patent application details additional methods for targeting specific mutations or single nucleotide polymorphisms (SNPs) associated with monogenic Parkinson's disease using RNA molecules and CRISPR nucleases. The application also covers the use of a second RNA molecule to induce a second double-strand break in the LRRK2 gene, potentially excising specific exons. The patent application aims to provide a precise and targeted approach for modifying genetic mutations linked to Parkinson's disease, offering potential therapeutic applications for treating or preventing the condition.

To know more about GlobalData’s detailed insights on AnGes, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies